Results 41 to 50 of about 28,989 (238)

Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.

Annals of Pharmacotherapy, 2019
Objective: To review the pharmacology, efficacy, and safety of the selective transthyretin inhibitor tafamidis for transthyretin amyloid cardiomyopathy (ATTR-CM). Data Sources: A PubMed (1966 to October 2019) and ClinicalTrials.
Andrews, Ebony, Ling, Hua, Ombengi, David, Park, Jonathan, Parker, Shanea, Egolum, Ugochukwu   +5 more
core   +3 more sources

Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology

Annals of Medicine, 2021
Background Hereditary Transthyretin-Related Amyloidosis, a clinically heterogeneous autosomal dominant disease caused by pathogenic variants in the TTR gene, is characterized by the deposition of insoluble misfolded protein fibrils.
Volha Skrahina, Ulrike Grittner, Christian Beetz, Thomas Skripuletz, Martin Juenemann, Heidrun H. Krämer, Katrin Hahn, Andreas Rieth, Volker Schaechinger, Monica Patten, Christian Tanislav, Stephan Achenbach, Birgit Assmus, Fabian Knebel, Stefan Gingele, Aliaksandr Skrahin, Jörg Hartkamp, Toni M. Förster, Sabine Roesner, Catarina Pereira, Arndt Rolfs   +20 more
doaj   +1 more source

Domino living donor liver transplantation of familial amyloid polyneuropathy patient - A case report - [PDF]

Anesthesia and Pain Medicine, 2020
Background Familial amyloid polyneuropathy (FAP) is caused by mutation in a gene transcribing transport protein produced mainly by the liver. Liver transplantation is required to stop FAP progression, but the pathology causes anesthetic management ...
Sungrok Cha, Jiwon Kim, Soo Joo Choi, Gaab Soo Kim   +3 more
doaj   +1 more source

A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy

Nature Communications, 2021
Transthyretin amyloid cardiomyopathy is a treatable but often unrecognized cause of heart failure. We derived and validated a machine learning model based on medical diagnostic codes that identifies heart failure patients at risk for wild-type ...
Ahsan Huda, Adam Castaño, Anindita Niyogi, Jennifer Schumacher, Michelle Stewart, Marianna Bruno, Mo Hu, Faraz S. Ahmad, Rahul C. Deo, Sanjiv J. Shah   +9 more
doaj   +1 more source

Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome

, 2013
Background Cardiac amyloidosis is a fatal disease whose prognosis and treatment rely on identification of the amyloid type. In our aging population transthyretin amyloidosis (ATTRwt) is common and must be differentiated from other amyloid types.
Banypersad, SM, Whelan, CJ, Lachmann, HJ, Gillmore, JD, Gibbs, SD, Hawkins, PN, McCarthy, CA, Sattianayagam, P, Rowczenio, D, Wechalekar, A, Venner, CP, Petrie, A, Dungu, J, Wassef, N, Pinney, JH, Gilbertson, JA   +15 more
core   +1 more source

Structure-Based Probe Reveals the Presence of Large Transthyretin Aggregates in Plasma of ATTR Amyloidosis Patients

JACC: Basic to Translational Science
Summary: Amyloidogenic transthyretin (ATTR) amyloidosis is a relentlessly progressive disease caused by the misfolding and systemic accumulation of amyloidogenic transthyretin into amyloid fibrils.
Rose Pedretti, BS, Lanie Wang, BS, Anna Yakubovska, MS, Qiongfang S. Zhang, BS, Binh Nguyen, PhD, Justin L. Grodin, MD, Ahmad Masri, MD, Lorena Saelices, PhD   +7 more
doaj   +1 more source

Accurate, strong, and stable reporting of choroid plexus epithelial cells in transgenic mice using a human transthyretin BAC

Fluids and Barriers of the CNS, 2018
Background Choroid plexus epithelial cells express high levels of transthyretin, produce cerebrospinal fluid and many of its proteins, and make up the blood-cerebrospinal fluid barrier. Choroid plexus epithelial cells are vital to brain health and may be
Brett A. Johnson, Margaret Coutts, Hillary M. Vo, Xinya Hao, Nida Fatima, Maria J. Rivera, Robert J. Sims, Michael J. Neel, Young-Jin Kang, Edwin S. Monuki   +9 more
doaj   +1 more source

Stroke volume and myocardial contraction fraction in transthyretin amyloidosis cardiomyopathy: A systematic review

Frontiers in Cardiovascular Medicine, 2023
BackgroundCardiac amyloidosis (CA) is primarily a restrictive cardiomyopathy in which the impairment of diastolic function is dominant. Despite this, the left ventricular ejection fraction (LVEF) may be depressed in the late stage of the disease, but it ...
Serenelli Matteo, Cantone Anna, Sanguettoli Federico, Maio Daniele, Fabbri Gioele, Dal Passo Beatrice, Pavasini Rita, Tonet Elisabetta, Passarini Giulia, Rapezzi Claudio, Campo Gianluca   +10 more
doaj   +1 more source

Technetium-99m-labeled pyrophosphate uptake in the rectum of a patient with wild-type transthyretin cardiac amyloidosis

Radiology Case Reports
Wild-type transthyretin amyloidosis is a disease characterized by deposition of transthyretin amyloid protein in systemic organs and tissues, especially the heart, lungs, tenosynovium, and ligaments.
Koji Takahashi, MD, PhD, Daisuke Sasaki, MRT, Shuhei Yamamoto, MD, Nobuhisa Yamamura, MLT, Yushi Utsunomiya, MD, Hiroe Morioka, MD, Shigeki Uemura, MD, Tomoki Sakaue, MD, PhD, Katsuji Inoue, MD, PhD   +8 more
doaj   +1 more source

Misdiagnosis of hereditary amyloidosis as AL (Primary) amyloidosis [PDF]

, 2002
Background: Hereditary, autosomal dominant amyloidosis, caused by mutations in the genes encoding transthyretin, fibrinogen A -chain, lysozyme, or apolipoprotein A-I, is thought to be extremely rare and is not routinely included in the differential ...
Booth, D.R., Gilbertson, J.A., Hawkins, P.N., Booth, S.E., Lachmann, H.J., Gillmore, J.D., Bybee, A., Pepys, M.B.   +7 more
core